Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Myelosuppression in Small-Cell Lung Cancer

June 2021 Vol 7 No 3

In February 2021, the FDA approved Cosela (trilaciclib; from G1 Therapeutics), as the first CDK4/6 inhibitor to reduce the frequency of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer, when used before chemotherapy with platinum plus etoposide or a topotecan-containing regimen. Cosela can prevent damage to bone marrow cells by blocking the CDK4/6 enzyme.

“For patients with extensive-stage small-cell lung cancer, protecting bone marrow function may help make their chemotherapy safer and allow them to complete their course of treatment on time and according to plan,” said Albert Deisseroth, MD, PhD, Medical Officer at the FDA’s Center for Drug Evaluation and Research. “Today’s approval of Cosela will give patients a treatment option that can reduce the occurrence of a common, harmful side effect of chemotherapy.”

The FDA approved Cosela based on data from 3 clinical trials with a total of 245 patients who received either intravenous Cosela or to placebo before chemotherapy. In all 3 studies, patients who received Cosela had a lower risk of serious neutropenia (inability to fight infection) than those who received placebo, and a shorter duration of serious neutropenia.

The most common side effects with Cosela were fatigue, increased levels of aspartate aminotransferase, headache, pneumonia, and deficiencies in calcium, potassium, and phosphate. Serious side effects included neutropenia, thrombocytopenia, anemia, leukopenia, and febrile neutropenia.

Recommended For You